In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...
X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time ...
Good morning, everyone, and thank you for joining us. We're excited to be speaking with you fresh off a highly successful American Epilepsy Society Meeting for Xenon. Before we begin, please note the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results